Cargando…
P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621512/ http://dx.doi.org/10.1097/01.HS9.0000890668.27643.97 |
| _version_ | 1784821573626101760 |
|---|---|
| author | Radford, John Adedayo, Toyin Ardavan, Arzhang Barrington, Sally F. Berkahn, Leanne Chauvie, Stephane Clifton-Hadley, Laura Collins, Graham P. Crump, Michael Cutter, David Edwards, Darren Hutchings, Martin Illidge, Tim Kirkwood, Amy A. Linton, Kim Moskowitz, Craig H. Patrick, Pip Phillips, Beth Shepherd, Lois Tonino, Sanne Trotman, Judith Williams, Joanna Doo, Nicole Wong |
| author_facet | Radford, John Adedayo, Toyin Ardavan, Arzhang Barrington, Sally F. Berkahn, Leanne Chauvie, Stephane Clifton-Hadley, Laura Collins, Graham P. Crump, Michael Cutter, David Edwards, Darren Hutchings, Martin Illidge, Tim Kirkwood, Amy A. Linton, Kim Moskowitz, Craig H. Patrick, Pip Phillips, Beth Shepherd, Lois Tonino, Sanne Trotman, Judith Williams, Joanna Doo, Nicole Wong |
| author_sort | Radford, John |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621512 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96215122022-11-01 P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma Radford, John Adedayo, Toyin Ardavan, Arzhang Barrington, Sally F. Berkahn, Leanne Chauvie, Stephane Clifton-Hadley, Laura Collins, Graham P. Crump, Michael Cutter, David Edwards, Darren Hutchings, Martin Illidge, Tim Kirkwood, Amy A. Linton, Kim Moskowitz, Craig H. Patrick, Pip Phillips, Beth Shepherd, Lois Tonino, Sanne Trotman, Judith Williams, Joanna Doo, Nicole Wong Hemasphere Early Stages Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621512/ http://dx.doi.org/10.1097/01.HS9.0000890668.27643.97 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Early Stages Radford, John Adedayo, Toyin Ardavan, Arzhang Barrington, Sally F. Berkahn, Leanne Chauvie, Stephane Clifton-Hadley, Laura Collins, Graham P. Crump, Michael Cutter, David Edwards, Darren Hutchings, Martin Illidge, Tim Kirkwood, Amy A. Linton, Kim Moskowitz, Craig H. Patrick, Pip Phillips, Beth Shepherd, Lois Tonino, Sanne Trotman, Judith Williams, Joanna Doo, Nicole Wong P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma |
| title | P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma |
| title_full | P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma |
| title_fullStr | P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma |
| title_full_unstemmed | P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma |
| title_short | P025: RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma |
| title_sort | p025: radar: an international phase iii, pet response-adapted, randomised trial in progress, comparing abvd±isrt with brentuximab vedotin+avd±isrt in patients with previously untreated limited-stage classical hodgkin lymphoma |
| topic | Early Stages |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621512/ http://dx.doi.org/10.1097/01.HS9.0000890668.27643.97 |
| work_keys_str_mv | AT radfordjohn p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT adedayotoyin p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT ardavanarzhang p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT barringtonsallyf p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT berkahnleanne p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT chauviestephane p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT cliftonhadleylaura p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT collinsgrahamp p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT crumpmichael p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT cutterdavid p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT edwardsdarren p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT hutchingsmartin p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT illidgetim p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT kirkwoodamya p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT lintonkim p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT moskowitzcraigh p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT patrickpip p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT phillipsbeth p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT shepherdlois p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT toninosanne p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT trotmanjudith p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT williamsjoanna p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma AT doonicolewong p025radaraninternationalphaseiiipetresponseadaptedrandomisedtrialinprogresscomparingabvdisrtwithbrentuximabvedotinavdisrtinpatientswithpreviouslyuntreatedlimitedstageclassicalhodgkinlymphoma |